Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, cubosome and hexosome carriers with antimicrobial peptides showed varied efficacy, with cubosomes protecting peptides from degradation and enhancing bactericidal effects in some cases, while hexosomes lacked antimicrobial activity.

This abstract provides information on various oral contraceptives, their potential hazardous interactions, and possible side effects, without presenting new research findings.

The researchers reported that fluconazole was only modestly effective for treating sporotrichosis, particularly for osteoarticular or visceral cases, and is best considered a second-line treatment.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.

In this study, an injectable self-healing bioactive nanoglass hydrogel showed promise for repairing normal and MRSA-infected skin wounds by inhibiting bacterial growth and reducing inflammation.

This source summarizes the new 2024 American Academy of Dermatology guidelines, emphasizing strong recommendations for topical and oral therapies like benzoyl peroxide, doxycycline, and isotretinoin in managing acne vulgaris, while outlining the importance of tailored treatments for diverse patient needs in Canadian practice.

This study found that once-daily oxiconazole cream effectively treats tinea infections, achieving at least 80% cure rates, and shows comparable efficacy to other antifungal creams with similar tolerability.

This study found that treatment with oral tofacitinib, alone or with other therapies, was associated with clinical improvement in most patients with recalcitrant lichen planopilaris.

This article reviews the multifaceted approach required for acne vulgaris treatment, emphasizing individualized combination therapies tailored to clinical severity and patient psychological profiles, but no new results are included.

This study explored the potential of the lysate and lipoteichoic acid from Lactiplantibacillus plantarum APsulloc 331261 to improve scalp seborrheic dermatitis by modulating inflammatory and lipogenesis pathways in vitro, suggesting potential as a natural treatment option.

This letter challenges an interpretation of results from a zinc lozenge trial that suggested patient perceptions of receiving treatment might indicate effective blinding, arguing this only holds for crossover studies.

This article reviews the treatment and characteristics of skin infections like carbuncles and furuncles related to Staphylococcus aureus, but presents no new clinical findings.

In a double-blind clinical trial, this study found that a gel containing chitosan-coated spironolactone nanoparticles effectively reduced acne lesions over 8 weeks without adverse skin effects, suggesting potential for enhanced acne treatment through targeted skin delivery.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This review discusses ongoing and past trials for novel acne treatments, focusing on topical agents with potential sebosuppressive, antimicrobial, or anti-inflammatory effects, without reporting new clinical results.

This study is investigating the efficacy and safety of proxalutamide, an androgen receptor antagonist, in treating severe or critically ill patients with COVID-19, aiming to provide new insights into potential therapeutic options. Results are not reported yet.

In this first-in-human study, BLZ-100, an intraoperative fluorescent imaging agent, was administered to 21 patients before skin cancer surgery and was found to be well tolerated without serious adverse effects, suggesting its potential to help distinguish cancerous from non-cancerous tissue based on fluorescence.

This study found that among patients with folliculitis decalvans, treatment with isotretinoin achieved the highest rate of stable remission compared to antibiotic regimens like clindamycin and rifampicin.

This study found that oral tetracycline hydrochloride significantly reduced the free fatty acid/triglyceride ratio in hair lipids of young men and women treating acne vulgaris, with or without additional ethyl lactate application.

This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.

In this study, amitraz was found to be an effective and well-tolerated treatment for resolving sarcoptic mange in alpacas, demonstrating no relapse over a 10-month follow-up.

This study found that garlic gel significantly improved the efficacy of topical betamethasone valerate in treating alopecia areata compared to placebo.

In this study, androgen deprivation, particularly through finasteride treatment, effectively reduced chronic bacterial prostatitis severity in rats, suggesting potential for improved treatment modalities combining finasteride and levofloxacin.

This paper reviews the current evidence regarding the off-label use of spironolactone for acne management, noting that despite its long-standing application in acne treatment, it has not yet received FDA approval for this indication.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

In this study, ethanamizuril was found to cause alopecia, biochemical changes, and organ damage at higher doses in rats, with a no-observed-adverse-effect level of 20 mg/kg over 30 days.

This review discusses the clinical significance of L-Lysine in treating various conditions and reports mixed findings on its effectiveness against herpes simplex virus infections, with no new experimental results presented.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.